New strategies to prevent restenosis

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalAmerican Journal of Cardiovascular Drugs
Volume1
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint

Pharmacology
Bioengineering
Therapeutics
Vascular Smooth Muscle
Angioplasty
Fertilization
Smooth Muscle Myocytes
Molecular Biology
Research Personnel
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{927603b82b314744aedd895cf3d72656,
title = "New strategies to prevent restenosis",
abstract = "The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.",
author = "Mark Kester and Peter Waybill and Mark Kozak",
year = "2001",
month = "1",
day = "1",
doi = "10.2165/00129784-200101020-00001",
language = "English (US)",
volume = "1",
pages = "77--83",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "2",

}

New strategies to prevent restenosis. / Kester, Mark; Waybill, Peter; Kozak, Mark.

In: American Journal of Cardiovascular Drugs, Vol. 1, No. 2, 01.01.2001, p. 77-83.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New strategies to prevent restenosis

AU - Kester, Mark

AU - Waybill, Peter

AU - Kozak, Mark

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.

AB - The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.

UR - http://www.scopus.com/inward/record.url?scp=0008455919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008455919&partnerID=8YFLogxK

U2 - 10.2165/00129784-200101020-00001

DO - 10.2165/00129784-200101020-00001

M3 - Review article

C2 - 14728037

AN - SCOPUS:0008455919

VL - 1

SP - 77

EP - 83

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -